The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections by Jugun, Kheeldass et al.
ORIGINAL PAPER
The safety and efficacy of high-dose daptomycin combined
with rifampicin for the treatment of Gram-positive
osteoarticular infections
Kheeldass Jugun & Pierre Vaudaux & Jorge Garbino &
Leonardo Pagani & Pierre Hoffmeyer & Daniel Lew &
Ilker Uçkay
Received: 7 February 2013 /Accepted: 26 February 2013 /Published online: 22 March 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract
Purpose Treatment of Gram-positive osteoarticular infec-
tions requires an adequate surgical approach combined with
intensive antimicrobial therapy. The aim of this study was to
evaluate the safety and efficacy of a combined regimen of
high-dose daptomycin and rifampicin, in patients with var-
ious types of Gram-positive osteoarticular infections.
Methods This single centre, non-comparative, prospective
study evaluated the safety and efficacy of a combined regimen
of intravenous daptomycin (8 mg/kg/day) and oral rifampicin
(600 mg/day) in patients with Gram-positive osteoarticular
infections, with a minimal follow-up of one year. Creatine
phosphokinase, transaminases, bilirubinaemia, and serum cre-
atinine, were measured at baseline and regular intervals.
Results The median daily doses of daptomycin and rifampi-
cin, administered for a median duration of 21 (range, 10–122)
days to 16 patients (median age, 63.5 years; 11 males,
five females) presenting with staphylococcal (n=15) or strep-
tococcal (n=1) osteoarticular infections, were 8.15 (range,
6.6–8.9) mg/kg/day and 600 (range, 600–900) mg/day, respec-
tively. The combined regimen of daptomycin and rifampicin
was well tolerated by all except one patient, without requiring
treatment adjustment or discontinuation. One patient developed
allergic responses probably due to rifampicin after 42 days.
Fifteen (94 %) patients showed favourable clinical and micro-
biological outcomes.
Conclusions The combined regimen of high-dose daptomycin
and rifampicin was well tolerated and may provide a useful
alternative to standard glycopeptide therapy for Gram-positive
osteoarticular infections.
Introduction
Treatment of osteoarticular infections due to coagulase-
negative staphylocococci (CNS), Staphylococcus aureus,
or Streptococcus sp, in particular those associated with
artificial devices used for osteosynthesis or permanent pros-
thetic implants [1], requires an adequate surgical approach
combined with long-term antimicrobial therapy. Very few
antimicrobial agents remain available for therapy of
osteoarticular infections that are due to multi-resistant
Gram-positive pathogens, in particular methicillin-resistant
S. aureus (MRSA). Besides glycopeptides that remain the
mainstay for therapy of MRSA deep-seated infections, some
recently developed agents that are active against both sus-
ceptible and multi-resistant, gram-positive pathogens in-
cluding MRSA, in particular daptomycin [2–6] and
linezolid [7, 8], have been recently evaluated for therapy
of osteoarticular infections.
Daptomycin is a lipopeptide antibiotic that has a rapid
bactericidal activity in vitro and in vivo, but this bactericidal
activity is concentration-dependent and its optimal expres-
sion may require plasma levels equivalent to eight times the
lipopeptide minimum inhibitory concentration (MIC) for
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some strains [9, 10]. The relatively high protein binding and
low volume of distribution of daptomycin recorded in
healthy volunteers [11] represent a difficult challenge for
defining a dosing schedule exerting optimal activity against
various categories of deep-seated bacterial infections.
A once-daily dosing regimen of 4 mg/kg/day daptomycin
was initially approved for the treatment of complicated skin
and skin-structure infections due to gram-positive bacteria
[12]. Subsequently, daptomycin was found effective for ther-
apy of S. aureus bacteremia and right-sided endocarditis at a
once-daily dosing regimen of 6 mg/kg/day [13]. While early
clinical studies with twice-daily regimens of daptomycin
raised concerns about potential myopathy characterised by
high elevations (>10-fold) in serum creatine phosphokinase
[9, 14], further pharmacokinetic studies demonstrated the
safety of higher doses of daptomycin, such as 8 mg/kg/day,
when they were administered once daily for 14 days in
healthy volunteers [11].
We performed a single centre, non-comparative, prospec-
tive study to evaluate the safety and efficacy of a combined
regimen of high-dose daptomycin (8 mg/kg/day) and rifam-
picin (600 mg/day), for treatment of patients with Gram-
positive osteoarticular infections.
Materials and methods
Patient eligibility
The design of our single-centre, prospective, non-
comparative study, which required the informed consent
of all patients included, was approved by the Ethics Com-
mittee of our institution and Swissmedic (No 08–061;
NAC 08–001). Patients aged 18 years or older, presenting
with osteoarticular infections at the Orthopaedic Clinic of
the Geneva University Hospital, were eligible for inclu-
sion. Pregnant or lactating women were excluded. Appro-
priate diagnoses included bone or/and joint infection that
was associated or not with osteosynthesis devices or or-
thopaedic prostheses, involving the presence of the same
microbial pathogen in several intraoperative or purulent,
deep specimens.
Patients were excluded if they had received other antimicro-
bial agents for more than 72 hours prior to the combined
regimen of daptomycin and rifampicin. Other exclusion criteria
involved documented allergic reactions to daptomycin or ri-
fampicin, or infections with microbial pathogens resistant to
any of those antibiotics. Patients with severe renal insufficiency
(creatinine clearance under 30mL/min), baseline creatine phos-
phokinase (CPK) values that were more than five times greater
than upper normal (188 Units/L) limits, or severe hepathopathy
(CHILD C with transaminases and/or biluribinemia over five
times greater than upper normal limits) were also excluded.
Due to the potentially adverse effects of the study drugs,
including hepatitis, all patients included were advised to refrain
from alcohol consumption during the study period.
Other exclusion criteria were epilepsy or receipt of major
immunosuppressive therapy (cyclosporine, rapamune,
tacrolimus, prednisone dosage over 20 mg/day).
Study design and treatment
All study patients with Gram-positive osteoarticular infections
received once-daily regimens of intravenous daptomycin
(8 mg/kg by 30-min infusion) combined with oral rifampicin
(600 mg/day). Treatment duration was determined by the
medical team and guided by the clinical evolution and surgical
treatment of each patient.
Clinical and laboratory parameters
The clinical evolution was evaluated by the medical staff at
baseline and weekly intervals throughout the whole duration
of daptomycin-rifampicin therapy. Ambulatory patients were
evaluated at the Policlinic of Surgery according to clinical
needs.
Clinical laboratory parameters were also measured at base-
line and checked weekly during daptomycin-rifampicin ther-
apy, including clinical chemistry and other blood parameters,
CPK, serum creatinine levels, aspartate aminotransferase
(ASAT) and alanine transaminase (ALAT), bilirubinemia. Mi-
crobiological cultures and antibiotic susceptibility testing
were processed under standard conditions.
Follow-up evaluation was performed six to eight weeks
after the end of daptomycin-rifampin therapy. Final follow-
up assessments were undertaken at least one year after the
end of antibiotic therapy.
Safety evaluation
Patients were frequently monitored for the incidence of
clinically significant adverse events during hospitalisation
and at intervals during follow-up out patient visits. The
incidence of adverse effects was also checked by laboratory
detection of significant elevations in enzymatic markers for
hepatic (upper normal limits: ASAT 42 units/L, ALAT 42
units/L), kidney (serum creatinine), or muscle (CPK) toxic-
ity (upper normal limit: 188 IU/L).
Discontinuation of the daptomycin-rifampicin protocol
was required in the event of of any major clinical side
effect (hepatitis with greater than five times elevation in
transaminases levels, renal insufficiency with a more than
two-fold increase in serum creatinine, CPK elevations>
500 IU/L), or in case of a treatment-emergent resistance
or microbiologically documented superinfection by anoth-
er bacterial species during therapy.
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Clinical response
The primary objective was to evaluate the safety profile of
the daptomycin-rifampicin combination. A secondary objec-
tive was the clinical efficacy of the daptomycin-rifampicin
combined therapy. The clinical efficacy was considered
successful if no major surgical procedure or no major
change in antibiotic therapy was required during the thera-
peutic protocol, and if clinical resolution and microbiolog-
ical eradication of the pathogen were assessed after at least
one-year follow-up period. Treatment failure was defined as
inadequate clinical response or microbiologically document-
ed relapse of the osteoarticular infection, occurring during
the daptomycin-rifampicin protocol or its follow-up period.
Statistical analyses
Categorical variables were expressed as percentages and
numerical data as median and range.
Results
Sixteen patients with osteoarticular infections were includ-
ed. Their detailed demographic, clinical, and laboratory data
are presented in Table 1. The median age was 63.5 (range,
26–85) years. Five (31 %) patients were females and 11
(69 %) were males. Thirteen (81 %) patients had implanted
devices, of which seven were for osteosynthesis and six for
arthroplasty. One patient had a vascular prosthesis.
Fifteen (94 %) patients had staphylococcal and one patient
had a streptococcal (Streptoccocus mitis) infections. Three
(17 %) patients were infected with methicillin-resistant Staph-
ylococcus epidermidis (MRSE), five (31 %) with methicillin-
susceptible S. aureus (MSSA), and seven (44 %) withMRSA.
Underlying conditions included diabetes for five (31 %)
patients, low-level immunosuppressive therapy for two pa-
tients, namely, onewith kidney graft and one with autoimmune
disease, and statin therapy for two diabetic patients with pe-
ripheral arterio-occlusive disease. One patient had hepatitis C.
The median duration of hospitalisation was 21.5 (range, six to
126) days. The median number of surgical procedures was two
(range, one to six).While five patients (31%) had a single surgical
procedure, 11 patients (69 %) had two or more procedures.
Daptomycin was i.v. administered once-daily at a median
dose of 8.15 (range, 6.6–8.9) mg/kg/day. Rifampicin was
orally administered once-daily at a median dose of 600
(range, 600–900) mg/day, to all patients except one who
received 900 mg/day (Table 1). Eleven patients received the
daptomycin-rifampicin regimen as first-line therapy and five
patients as second-line therapy.
The combined regimen of high-dose daptomycin and
rifampicin was administered for a median duration of 21
(range, ten to 122) days and was well supported by all
patients, including two who received concomitant statin
therapy. Only minor side effects (mild fatigue or mild my-
algia) occurred in two patients. This good tolerance was
assessed by laboratory testing of enzymatic toxicity
markers, which showed no clinically significant elevation
throughout antibiotic therapy for any of the patients. Max-
imal values of repeatedly assayed CPK ranged from five to
305 IU/L (median, 88 IU/L) (Table 1). Maximal values of
transaminases ranged from 15 to 52 IU/L (median,
20.5 IU/L). Moreover, serum creatinine levels did not
change significantly during therapy.
While no significant, clinically or laboratory-documented
adverse effect occurred that required adjustment or discon-
tinuation of daptomycin therapy, one patient developed an
ileus and a rash clinically attributed to rifampicin after
42 days of combined antibiotic therapy, which led to dis-
continuation of rifampicin administration.
Evaluation of treatment outcomes was performed over a
median follow-up period of 473 (range, 373–900) days.
This global evaluation represented the sum of all medical
and surgical procedures, including additional antimicrobial
therapy that was administered to 11 patients after the com-
bined regimen of rifampicin and daptomycin. Six of the
seven patients with osteosynthesis devices, and five of six
patients with arthroplasty prostheses, received additional,
orally-administered antibiotic regimens after leaving the
hospital for median periods of 25 (range, 16–344) and 170
(range, 111–658) days, respectively.
A single patient who was diagnosed with bacteraemia
combined with a para-valvular abscess during daptomycin-
rifampicin therapy and who died from endocarditis and
sepsis on day 15 was not included in outcome evaluation.
All other 15 patients had an infection-free follow-up, in-
cluding two patients who had bacteraemia during therapy,
involving the same MSSA osteoarticular pathogen but with-
out endocardial involvement, and another patient who had a
vascular prosthesis that led to limb amputation. No emer-
gence of daptomycin or rifampicin-resistant isolate occurred
in any patient, which would have required their exclusion
from the therapeutic protocol.
Orthopaedic implants were removed in eight patients.
Prostheses were retained in three patients, permanently re-
moved in one patient, or totally or partially exchanged in
two patients. Osteosynthesis devices were retained in one
patient, permanently removed in four patients, and ex-
changed in two patients.
Discussion
Recent studies indicate a growing interest in the design of
novel therapeutic protocols for deep-seated multi-resistant
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Gram-positive infections, as alternatives to the standard
glycopeptide therapy [2–8]. Daptomycin has attractive prop-
erties for treating osteoarticular infections, because of its
rapid bactericidal activity against susceptible as well as
multi-resistant, Gram-positive isolates. Emergence of
daptomycin resistance remains a rare event in staphylococci
and is limited to individual case reports [9, 10]. While recent
clinical data assessed the efficacy and safety of high-dose
daptomycin in Gram-positive osteoarticular infections
[2–6], no specific study evaluated the combined regimen
of high-dose daptomycin (8 mg/kg/day) and rifampicin
(600 mg/day) in this context. In view of the quite variable
(from 300 to 1,200 mg/day) regimens of rifampicin that
have been described in the literature, official recommenda-
tions for a standard rifampicin regimen in the context of
osteoarticular infections would be most appropriate. Never-
theless, the median daily dose of 600 mg/day of rifampicin
is congruent with Swiss and US expert recommendations
and warrant continuously active levels of this antimicrobial
agent throughout therapy.
The safety of high dose (over 6 mg/kg/day) daptomycin,
concomitant or not with statin therapy, was evaluated by
Parra-Ruiz et al. in 43 and 25 patients with prosthetic joint
and diabetic infections, respectively [4]. While resolution of
infection was documented in 33/43 (77 %) patients with
prosthetic joint infections and 17/25 (68 %) patients with
diabetic foot infections, the proportion of staphylococcal
infections in those two groups was not indicated. Interest-
ingly, the overall rate of biochemically detected muscular
toxicity in all daptomycin-treated patients (n=104), defined
as CPK levels>1,000 UI/L, was approximately 10 %. In
contrast, no clinically significant toxicity was observed and
daptomycin therapy was completed in all cases. This study
also reported that concomitant administration of daptomycin
and statins was safe and not associated with an increased risk
of rhabdomyolysis or myositis. In another retrospective
study, Corona Perez-Cardona et al. described 20 patients
with knee or hip periprosthetic joint infections, who received
an average daptomycin dose of 6.6 mg/kg/day for a mean
duration of 44.9 days [3]. Only 14 of those patients were
evaluable for outcome, yielding an overall success rate of
78.6 %. Since only four patients were infected with MSSA or
MRSA in that study, the significance of daptomycin efficacy
data against S. aureus prosthetic joint infections is limited.
Noteworthy, severe side effects occurred in two patients,
namely, one case of acute renal failure due to massive rhab-
domyolysis and one of eosinophilic pneumonia, which re-
solved with appropriate therapy after the end of daptomycin
administration [3].
The safety and efficacy of high dose daptomycin for treating
osteoarticular infections was confirmed by two recent studies,
the first one targeting patients with prosthetic devices under-
going two-stage revision arthroplasty [6], and the second of
non-hardware associated osteomyelitis patients [5]. In both
studies, clinically and laboratory documented daptomycin-
related adverse effects ranged from five to over 20 %.
It is remarkable that our prospective, observational study
did not reveal any daptomycin-related, clinically significant
side effects, in patients with osteoarticular infections treated
with combined regimens of high-dose daptomycin and rifam-
picin for several weeks. Tolerability of the daptomycin-
rifampicin regimen was confirmed by laboratory assessment
of enzymatic markers for muscular, liver or kidney toxicity,
which showed no significant elevations, except for one patient
who developed allergic responses probably due to rifampicin.
A significant proportion of those patients had underlying
diseases, such as diabetes, immunocompromised conditions
or vascularisation problems and were facing multiple surgical
procedures. Finally, additional risk factors for antibiotic treat-
ment failure were the presence of implanted devices or pros-
theses in most patients, combined with the presence of multi-
resistant strains of S. aureus or S. epidemidis.
While recent clinical studies afford no evidence for a dose-
dependent daptomycin-related muscular toxicity, there is a
growing consensus for an improved therapeutic efficacy of
daptomycin against deep-seated Gram-positive pathogens,
when this antibiotic is used at high-dose regimens
(over 6 mg/kg/day). In particular, high-dose daptomycin is
assumed to improve daptomycin’s bone penetration [3, 4].
The dose-related efficacy of daptomycin was also observed
in animal models of foreign body infections [15–17]. Taken
together, the safety and efficacy profiles of the combined
regimen of high-dose daptomycin and rifampicin provide a
useful alternative to standard glycopeptide therapy for
osteoarticular infections due to susceptible as well as multi-
resistant Gram-positive pathogens. Further studies evaluating
a larger group of patients with Gram-positive orthopaedic
infections are required to evaluate the rate of clinically signif-
icant side effects and the potential occurrence of therapy
failures or/and emergence of daptomycin resistance.
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